In patients receiving highly emetogenic
Help stop CINV before it starts
Include EMEND or EMEND for Injection in your antiemetic regimen with a 5-HT3 antagonist and a corticosteroid
A regimen including a 5-HT3 antagonist, corticosteroid, and EMEND or EMEND for Injection — CINV prevention for 5 days from Cycle 1, Day 11,2Review efficacy data
EMEND and EMEND for Injection offer flexible dosing options for patients receiving highly emetogenic chemotherapy.Explore dosing options
CINV risk factors
Before Cycle 1, identify your patients’ individual risk factors for CINV. Because with every additional risk factor, the risk of emesis increases.3Review CINV risk factors
1. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112–4119.
2. Grunberg SM, Chua DT, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol. Published online ahead of print March 7, 2011. jco.ascopubs.org/cgi/doi/10.1200/JCO.2010.31.7859.
3. Osoba D, Zee B, Pater J, et al; for Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol. 1997;15(1):116–123.
CINV=chemotherapy-induced nausea and vomiting.